CytomX Therapeutics Inc (NASDAQ:CTMX) CFO Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock in a transaction on Thursday, November 1st. The stock was sold at an average price of $15.00, for a total transaction of $45,000.00. Following the sale, the chief financial officer now directly owns 8,928 shares of the company’s stock, valued at $133,920. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.
Debanjan Ray also recently made the following trade(s):
- On Monday, October 1st, Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock. The stock was sold at an average price of $18.46, for a total transaction of $55,380.00.
- On Tuesday, September 4th, Debanjan Ray sold 3,000 shares of CytomX Therapeutics stock. The stock was sold at an average price of $22.39, for a total transaction of $67,170.00.
Shares of NASDAQ:CTMX opened at $12.75 on Wednesday. CytomX Therapeutics Inc has a 52 week low of $12.75 and a 52 week high of $35.00.
CytomX Therapeutics (NASDAQ:CTMX) last issued its earnings results on Tuesday, November 6th. The biotechnology company reported ($0.53) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.11). CytomX Therapeutics had a negative return on equity of 74.84% and a negative net margin of 44.46%. Analysts expect that CytomX Therapeutics Inc will post -1.58 EPS for the current year.
A number of research firms have recently issued reports on CTMX. BidaskClub downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 15th. HC Wainwright set a $32.00 price objective on shares of CytomX Therapeutics and gave the stock a “buy” rating in a report on Wednesday, October 24th. ValuEngine downgraded shares of CytomX Therapeutics from a “buy” rating to a “hold” rating in a report on Monday, September 17th. Cann reiterated a “hold” rating on shares of CytomX Therapeutics in a research report on Tuesday. Finally, Zacks Investment Research cut shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, October 9th. Two analysts have rated the stock with a sell rating, three have given a hold rating and seven have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and a consensus target price of $34.88.
A number of large investors have recently modified their holdings of CTMX. UBS Group AG raised its position in CytomX Therapeutics by 311.3% in the 1st quarter. UBS Group AG now owns 45,937 shares of the biotechnology company’s stock worth $1,307,000 after purchasing an additional 34,767 shares during the period. WINTON GROUP Ltd purchased a new position in CytomX Therapeutics in the 1st quarter worth $205,000. Allianz Asset Management GmbH raised its position in CytomX Therapeutics by 7.4% in the 1st quarter. Allianz Asset Management GmbH now owns 58,739 shares of the biotechnology company’s stock worth $1,671,000 after purchasing an additional 4,036 shares during the period. Xact Kapitalforvaltning AB purchased a new position in CytomX Therapeutics in the 2nd quarter worth $206,000. Finally, Essex Investment Management Co. LLC purchased a new position in CytomX Therapeutics in the 2nd quarter worth $502,000. Institutional investors own 71.53% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another website, it was copied illegally and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/11/07/debanjan-ray-sells-3000-shares-of-cytomx-therapeutics-inc-ctmx-stock.html.
CytomX Therapeutics Company Profile
CytomX Therapeutics, Inc operates as an oncology-focused biopharmaceutical company in the United States. The company develops a novel class of investigational antibody therapeutics based on its Probody technology platform for the treatment of cancer. Its product candidates in clinical stage include CX-072, a Probody therapeutic targeting programmed cell death ligand 1 anti-cancer target; CX-2009, a Probody drug conjugate (PDC) against CD166 novel tumor antigen; BMS-986249, a CTLA-4 Probody therapeutic drug; CX-2029, a PDC targeting CD71; and CX-188, a Probody therapeutic targeting PD-1 anti-cancer target.
See Also: Cost of Debt
Receive News & Ratings for CytomX Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytomX Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.